Clinical Trial Insights
Welcome to Cytel’s Insights hub—your go-to destination for the latest news, event updates, and expert insights on advanced analytical methods and data science. Come on in!
Unlock the Path to Successful EU JCA Submissions
Your Essential Guide to Navigating the New Era of Joint Clinical Assessments
The European Union’s Joint Clinical Assessment (JCA) is transforming how clinical effectiveness is evaluated across Member States, ushering in a unified, more efficient approach to health technology assessments. Our latest eBook, “Unlock the Path to Successful EU JCA Submissions,” is a must-read for pharmaceutical companies and technology developers aiming to stay ahead in this evolving regulatory landscape.
With expert insights and actionable strategies, this comprehensive guide empowers you to align your clinical, regulatory, and market access efforts for optimal success under the new EU JCA framework.
Read morePerspectives
Our experts share cutting-edge insights, industry trends, and in-depth analyses spanning the full spectrum of drug lifecycle management, from initial development through to successful commercialization.
News and Events
Stay up to date with the latest news and events here at Cytel and beyond. We will inform you about the upcoming industry events, our participation and contribution, keeping you connected and in the know.
World EPA Congress 2026
PHUSE APAC Connect 2026
Webinar – Enabling the Shift to Clinical Data Science and Engineering for Modern Trials
Webinaire – Accès Précoce vs Remboursement : Quels écarts de prix ?
Resource Library
The Cytel Library is always open—explore our extensive collection of articles, white papers, case studies, and more to discover how we are shaping the future of drug development.
White Paper – ICH E20 Ushers in a New Era for Adaptive Designs in Clinical Development
eBook – The Good Data Submission Doctor 2025
eBook – Rare Disease Clinical Trials: Design Strategies and Regulatory Considerations
E-Book – The Innovation Illusion
Publications
Stay up to date with our latest peer-reviewed publications on our Cytel pubmed page.
Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials. Khashayar Azimpour, Patricia Dorling, Irene Koulinska, Swati Kunduri, Zhiyi Lan, Julia Poritz, Gabriel Tremblay & Angie Raad-Faherty. Advances in Therapy 2025
Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps, Joshua S. Jacobs, Joseph K. Han, Jason K. Lee, Tanya M. Laidlaw, Nicole L. Martin, Scott Caveney, Christopher S. Ambrose, Neil Martin, Joseph D. Spahn & Flavia C. L. Hoyte, Advances in Therapy 2025
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer. Struebing A, McKibbon C, Ruan H, Mackay E, Dennis N, Velummailum R, He P, Tanaka Y, Xiong Y, Springford A, Rosenlund M., J Comp Eff Res. 2024
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis. Amonkar MM, Abderhalden LA, Fox GE, Frederickson AM, Grira T, Gozman A, Malhotra U, Malbecq W, Akers KG., Future Oncol. 2024
Claim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug’s probability of success and plot a clearer route to market.
